Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Acute Myeloid Leukemia With FLT3/ITD Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01349049
What this trial is testing

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 90
Large-scale testing (Phase 3)WithdrawnNCT04676243
What this trial is testing

Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML

Who this might be right for
Acute Myeloid Leukemia
University Hospital Heidelberg
Testing effectiveness (Phase 2)Looking for participantsNCT06022003
What this trial is testing

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
AML, AdultRefractory AMLRelapsed Adult AML+2 more
French Innovative Leukemia Organisation 33
Testing effectiveness (Phase 2)Looking for participantsNCT06824168
What this trial is testing

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Who this might be right for
Acute Myeloid LeukemiaLeukemia
Daiichi Sankyo 130
Early research (Phase 1)Looking for participantsNCT07162116
What this trial is testing

Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 45
Large-scale testing (Phase 3)Study completedNCT02039726
What this trial is testing

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Who this might be right for
AML
Daiichi Sankyo 367
Not applicableStudy completedNCT04788420
What this trial is testing

Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD MutationHematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University 456
Testing effectiveness (Phase 2)Study completedNCT02428543
What this trial is testing

Ponatinib for FLT3-ITD Acute Myelogenous Leukemia

Who this might be right for
Acute Myeloid Lukemia
Versailles Hospital 49
Testing effectiveness (Phase 2)Temporarily pausedNCT04278768
What this trial is testing

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Curis, Inc. 366
Testing effectiveness (Phase 2)Study completedNCT02728050
What this trial is testing

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Biphenotypic LeukemiaAcute Myeloid Leukemiade Novo Myelodysplastic Syndrome+2 more
University of Washington 84
Testing effectiveness (Phase 2)Study completedNCT01477606
What this trial is testing

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Who this might be right for
Acute Myeloid Leukemia
University of Ulm 451
Testing effectiveness (Phase 2)Study completedNCT01534260
What this trial is testing

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype

Who this might be right for
Acute Myeloid Leukemia
Hamid Sayar 37
Testing effectiveness (Phase 2)Study completedNCT01565668
What this trial is testing

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo 76
Testing effectiveness (Phase 2)Study completedNCT02196857
What this trial is testing

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT00989261
What this trial is testing

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 333
Early research (Phase 1)Ended earlyNCT04477291
What this trial is testing

CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Aptose Biosciences Inc. 45
Early research (Phase 1)Ended earlyNCT04496999
What this trial is testing

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

Who this might be right for
AML, Adult
Insel Gruppe AG, University Hospital Bern 2
Early research (Phase 1)Looking for participantsNCT05024552
What this trial is testing

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
H. Lee Moffitt Cancer Center and Research Institute 22
Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT05199051
What this trial is testing

Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

Who this might be right for
AMLLeukaemia (Acute Myeloid)
Centre Antoine Lacassagne 19
Next Page